News

Latham-Backed Drug Developer's Statements Can't Be Proven False, N.D. Cal. Judge Finds

U.S. District Judge Jon S. Tigar entered a judgment for ChemoCentryx Inc. on Aug. 15, writing that all of the statements the shareholder plaintiff had alleged were false or misleading were opinions ...
TipRanks on MSN2d

Akero Therapeutics’ Efruxifermin Study: A Potential Game-Changer for NASH Treatment

Akero Therapeutics (($AKRO)) announced an update on their ongoing clinical study. Akero Therapeutics is conducting a Phase 3 study titled ‘A Phase ...

Latham Wins Dismissal of Securities Action Involving Liver Disease Drug Developer

The case involved a clinical trial of Akero's only product, a drug candidate aimed at treating a liver disease. It's the ...
TipRanks on MSN3d

Akero Therapeutics’ Phase 3 NASH Study: A Potential Game-Changer?

Akero Therapeutics (($AKRO)) announced an update on their ongoing clinical study. Akero Therapeutics is conducting a Phase 3 study titled A Phase ...
BioPharma Dive4d

Novo’s Wegovy becomes first GLP-1 drug approved for MASH

The FDA clearance sets Novo’s medicine up for a market battle with Madrigal Pharmaceuticals’ fast-selling Rezdiffra.